F. E. Sevryukov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
F. E. Sevryukov has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Viatcheslav V. Polkin
National Medical Research Radiological Centre, Ministry of Health of Russia
8 shared publications - Sergey Anatolyevich Ivanov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
7 shared publications - Alexey A. Ilyin
National Medical Research Radiological Centre, Ministry of Health of Russia
4 shared publications - Andrei Dmitrievich Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
4 shared publications A. D. Kaprin
National Medical Research Radiological Center, Ministry of Health of Russia
2 shared publications- A. D. Kaprin
National Medical Research Radiological Centre, Ministry of Health of Russia
2 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 43-49
Results of intraoperative photodynamic therapy in T1–2 laryngeal cancer
Introduction. Laryngeal cancer is an important malignancy of the head and neck, with an estimated incidence of 238,000 cases per year. The main risk factors are smoking, human papillomavirus infection, and exposure to occupational carcinogens. Treatment of laryngeal cancer with T1–2 includes surgery and radiation therapy, but both methods have disadvantages: there is a risk of relapse after radiation therapy, and functional impairment after surgery, which necessitates optimization of treatment methods. photodynamic therapy is a promising organ-preserving method based on the targeted destruction of tumor cells by activating the photosensitizer accumulated in them with visible red light.Materials and methods. The study analyzed the results of combined treatment with intraoperative photodynamic therapy in 74 patients with laryngeal cancer from 2017 to 2023. Inclusion criteria: morphologically confirmed squamous cell carcinoma of the larynx, T1–2 tumor extent and absence of distant metastases. patients were administered photosensitizer (chlorin E6) intravenously 3 hours before surgery. Surgical treatment included endolaryngeal or open laryngeal resections followed by intraoperative photodynamic therapy on the bed of the removed tumor. Oncological and functional results were then assessed for 24 months.Results. Local recurrence was recorded in 2 (2.7 %) patients in the 1st year and in 3 (4.17 %) patients in the 2nd year. Overall survival was 100 %, larynx preservation was 95.9 %. In the group with a positive resection margin (n = 11), progression was noted in 2 patients. Respiratory, swallowing and vocal functions were restored in all patients. No complications associated with photodynamic therapy were registered.Conclusion. The high efficiency of a combined approach involving the use of intraoperative photodynamic therapy in early-stage laryngeal cancer has been demonstrated. This method has provided good oncological and functional results. In some cases, it allows you to avoid adjuvant radiation therapy, reduce the risk of complications and shorten the rehabilitation period. further studies of the long-term results of such a combined method will help assess the prospects for its implementation in clinical practice.
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 43-49
Open AccessResults of intraoperative photodynamic therapy in T1–2 laryngeal cancer
Introduction. Laryngeal cancer is an important malignancy of the head and neck, with an estimated incidence of 238,000 cases per year. The main risk factors are smoking, human papillomavirus infection, and exposure to occupational carcinogens. Treatment of laryngeal cancer with T1–2 includes surgery and radiation therapy, but both methods have disadvantages: there is a risk of relapse after radiation therapy, and functional impairment after surgery, which necessitates optimization of treatment methods. photodynamic therapy is a promising organ-preserving method based on the targeted destruction of tumor cells by activating the photosensitizer accumulated in them with visible red light.Materials and methods. The study analyzed the results of combined treatment with intraoperative photodynamic therapy in 74 patients with laryngeal cancer from 2017 to 2023. Inclusion criteria: morphologically confirmed squamous cell carcinoma of the larynx, T1–2 tumor extent and absence of distant metastases. patients were administered photosensitizer (chlorin E6) intravenously 3 hours before surgery. Surgical treatment included endolaryngeal or open laryngeal resections followed by intraoperative photodynamic therapy on the bed of the removed tumor. Oncological and functional results were then assessed for 24 months.Results. Local recurrence was recorded in 2 (2.7 %) patients in the 1st year and in 3 (4.17 %) patients in the 2nd year. Overall survival was 100 %, larynx preservation was 95.9 %. In the group with a positive resection margin (n = 11), progression was noted in 2 patients. Respiratory, swallowing and vocal functions were restored in all patients. No complications associated with photodynamic therapy were registered.Conclusion. The high efficiency of a combined approach involving the use of intraoperative photodynamic therapy in early-stage laryngeal cancer has been demonstrated. This method has provided good oncological and functional results. In some cases, it allows you to avoid adjuvant radiation therapy, reduce the risk of complications and shorten the rehabilitation period. further studies of the long-term results of such a combined method will help assess the prospects for its implementation in clinical practice.
- Open Access
- 30 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (4) , 37-47
Sentinel lymph node biopsy experience in squamous cell carcinoma of the oral mucosa сT1–2N0M0
Introduction. Head and neck cancer is the 7th most common malignancy worldwide; squamous cell carcinoma of the oral mucosa are almost a third of tumors of that localization. Metastatic lesions of the neck lymph nodes are an unfavorable prognostic factor for malignant tumors of that location since it is associated with a 50 % decrease in overall survival. In this regard, the detection of metastases to the neck lymph nodes is an important component of high-quality oncological care for patients with that pathology.Aim. To evaluate the efficiency of sentinel lymph node biopsy in squamous cell carcinoma of cavity of mouth mucosa cT1–2N0М0.Materials and methods. 72 patients were included in trial at the age from 21 to 74 (mean 57.3) with confirmed squamous cell carcinoma of cavity of mouth mucosa cT1–2N0М0. No evidence of regional metastasis, by preoperative examination, including ultrasound, computed tomography with intravenous contrast was observed. All patients received radioisotope research to determine localization of sentinel lymph nodes, and then biopsy of that nodes was performed. Before obtaining information about the status of the sentinel lymph node, radical neck dissection was not performed. Pathology report with immunohistochemical investigation was performed by pathologist of A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia.Results. When assessing efficiency of sentinel lymph node method, true positives results (detection of metastasis in sentinel lymph node) were achieved in 3 (4.17 %) out of 72 cases. Follow up time was from 1 to 69 months. Among those cases, where metastasis in sentinel lymph nodes were not detected, relapse in regional lymph nodes was developed in 3 (4.35 %) out of 69 cases. Radical neck dissection was performed in cases with metastasis in sentinel lymph nodes. The specificity of method was 95 %, the predictive value of a negative result was 0.04.Conclusion. Sentinel lymph neck node biopsy is an effective method of subclinical locoregional metastases detection in cancer of oral mucosa cT1–2N0M0. In our study of sentinel lymph neck node biopsy, oncological outcomes were comparable to radical neck dissection, with fewer postoperative complications.
- 30 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (4) , 37-47
Open AccessSentinel lymph node biopsy experience in squamous cell carcinoma of the oral mucosa сT1–2N0M0
Introduction. Head and neck cancer is the 7th most common malignancy worldwide; squamous cell carcinoma of the oral mucosa are almost a third of tumors of that localization. Metastatic lesions of the neck lymph nodes are an unfavorable prognostic factor for malignant tumors of that location since it is associated with a 50 % decrease in overall survival. In this regard, the detection of metastases to the neck lymph nodes is an important component of high-quality oncological care for patients with that pathology.Aim. To evaluate the efficiency of sentinel lymph node biopsy in squamous cell carcinoma of cavity of mouth mucosa cT1–2N0М0.Materials and methods. 72 patients were included in trial at the age from 21 to 74 (mean 57.3) with confirmed squamous cell carcinoma of cavity of mouth mucosa cT1–2N0М0. No evidence of regional metastasis, by preoperative examination, including ultrasound, computed tomography with intravenous contrast was observed. All patients received radioisotope research to determine localization of sentinel lymph nodes, and then biopsy of that nodes was performed. Before obtaining information about the status of the sentinel lymph node, radical neck dissection was not performed. Pathology report with immunohistochemical investigation was performed by pathologist of A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia.Results. When assessing efficiency of sentinel lymph node method, true positives results (detection of metastasis in sentinel lymph node) were achieved in 3 (4.17 %) out of 72 cases. Follow up time was from 1 to 69 months. Among those cases, where metastasis in sentinel lymph nodes were not detected, relapse in regional lymph nodes was developed in 3 (4.35 %) out of 69 cases. Radical neck dissection was performed in cases with metastasis in sentinel lymph nodes. The specificity of method was 95 %, the predictive value of a negative result was 0.04.Conclusion. Sentinel lymph neck node biopsy is an effective method of subclinical locoregional metastases detection in cancer of oral mucosa cT1–2N0M0. In our study of sentinel lymph neck node biopsy, oncological outcomes were comparable to radical neck dissection, with fewer postoperative complications.
- Open Access
- 14 December 2021
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 11 (4) , 73-80
Characteristics of composition a lymphoid infiltrate in the tongue squamous cell carcinoma
Introduction. Squamous cell carcinoma of the tongue is the most common oral cancer. The tumor microenvironment has a significant impact on tumor progression; therefore, better understanding of its characteristics is crucial for the treatment strategy, since in some cases it modifies the tumor microenvironment resulting in tumor resistance to therapy.Study objective – to compare the number of CD8+Т-lymphocytes, CD57+NK-cells, and CD20+B-lymphocytes in the microenvironment of tongue squamous cell carcinoma in patients receiving and not receiving neoadjuvant chemoradiotherapy.Materials and methods. We performed immunohistochemical examination of specimens from 67 patients with tongue squamous cell carcinoma who did not receive neoadjuvant chemoradiotherapy. Eleven patients were diagnosed with well differentiated tumors (G1); 21 patients had moderately differentiated tumors (G2); and 35 patients had poorly differentiated tumors (G3). T1 tumors were observed in 11 individuals, T2 tumors – in 26 individuals, T3 tumors – in 26 individuals, and T4 tumors – in 4 individuals. We also examined 30 patients who had undergone neoadjuvant chemoradiotherapy, including external beam radiotherapy (total dose of 60 Gy) and a cycle of polychemotherapy (cisplatin and 5‑fluorouracil). Of them, 6 patients had T1 tumors, 17 patients – T2 tumors, 5 patients – T3 tumors, and 2 patients – T4 tumors. We measured the areas occupied by CD8+T-lymphocytes, CD20+B-lymphocytes, and CD57+NK-cells in the hot spots in the tumor microenvironment.Results. The number of CD8+T-lymphocytes in the tumor microenvironment was higher in patients after neoadjuvant chemoradiotherapy than in those who did not receive it (р = 0.000), whereas the number of CD20+B-lymphocytes was lower after neoadjuvant chemoradiotherapy. The area occupied by CD57+NK-cells in the hot spots of the tumor microenvironment did not differ significantly before and after therapy (p 0.05).Conclusion. Thus, neoadjuvant chemoradiotherapy in patients with tongue squamous cell carcinoma caused an increase in the number of CD8+T-lymphocytes, a decrease in the number of CD20+B-lymphocytes in the tumor microenvironment, and had no effect on the population of CD57+NK-cells.
- 14 December 2021
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 11 (4) , 73-80
Open AccessCharacteristics of composition a lymphoid infiltrate in the tongue squamous cell carcinoma
Introduction. Squamous cell carcinoma of the tongue is the most common oral cancer. The tumor microenvironment has a significant impact on tumor progression; therefore, better understanding of its characteristics is crucial for the treatment strategy, since in some cases it modifies the tumor microenvironment resulting in tumor resistance to therapy.Study objective – to compare the number of CD8+Т-lymphocytes, CD57+NK-cells, and CD20+B-lymphocytes in the microenvironment of tongue squamous cell carcinoma in patients receiving and not receiving neoadjuvant chemoradiotherapy.Materials and methods. We performed immunohistochemical examination of specimens from 67 patients with tongue squamous cell carcinoma who did not receive neoadjuvant chemoradiotherapy. Eleven patients were diagnosed with well differentiated tumors (G1); 21 patients had moderately differentiated tumors (G2); and 35 patients had poorly differentiated tumors (G3). T1 tumors were observed in 11 individuals, T2 tumors – in 26 individuals, T3 tumors – in 26 individuals, and T4 tumors – in 4 individuals. We also examined 30 patients who had undergone neoadjuvant chemoradiotherapy, including external beam radiotherapy (total dose of 60 Gy) and a cycle of polychemotherapy (cisplatin and 5‑fluorouracil). Of them, 6 patients had T1 tumors, 17 patients – T2 tumors, 5 patients – T3 tumors, and 2 patients – T4 tumors. We measured the areas occupied by CD8+T-lymphocytes, CD20+B-lymphocytes, and CD57+NK-cells in the hot spots in the tumor microenvironment.Results. The number of CD8+T-lymphocytes in the tumor microenvironment was higher in patients after neoadjuvant chemoradiotherapy than in those who did not receive it (р = 0.000), whereas the number of CD20+B-lymphocytes was lower after neoadjuvant chemoradiotherapy. The area occupied by CD57+NK-cells in the hot spots of the tumor microenvironment did not differ significantly before and after therapy (p 0.05).Conclusion. Thus, neoadjuvant chemoradiotherapy in patients with tongue squamous cell carcinoma caused an increase in the number of CD8+T-lymphocytes, a decrease in the number of CD20+B-lymphocytes in the tumor microenvironment, and had no effect on the population of CD57+NK-cells.
- Open Access
- 8 August 2021
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 11 (2) , 64-71
Thyroid carcinoma with thymus-like differentiation (CASTLE) tumor: а сase report
Thyroid carcinoma with thymus-like differentiation (Carcinoma Showing Thymus-Like Differentiation, CASTLE) is an extremely rare disease. It arises from the thymus tissue ectopic into the tissue of the thyroid gland, usually in patients 40–50 years old. In this work, we present an observation of the development of CASTLE in a patient at a young age. A 21-year-old woman was admitted to our clinic with a volumetric education in the projection of the left lobe of the thyroid gland. Ultrasound revealed a 5-centimeter thyroid tumor. Surgery was performed in the scope of thyroidectomy, selective cervical dissection (level VI). Morphological and immunohistochemical studies showed that cancer has a thymus-like differentiation (CASTLE). After 32 months, she recurred to the lymph nodes of the neck (level IV on the left). She underwent repeated surgery, after which she was observed without signs of relapse for 120 months. The rarity of the pathology leads to difficulties in establishing a diagnosis at the preoperative stage and in choosing the optimal treatment tactics during treatment and further follow-up.
- 8 August 2021
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 11 (2) , 64-71
Open AccessThyroid carcinoma with thymus-like differentiation (CASTLE) tumor: а сase report
Thyroid carcinoma with thymus-like differentiation (Carcinoma Showing Thymus-Like Differentiation, CASTLE) is an extremely rare disease. It arises from the thymus tissue ectopic into the tissue of the thyroid gland, usually in patients 40–50 years old. In this work, we present an observation of the development of CASTLE in a patient at a young age. A 21-year-old woman was admitted to our clinic with a volumetric education in the projection of the left lobe of the thyroid gland. Ultrasound revealed a 5-centimeter thyroid tumor. Surgery was performed in the scope of thyroidectomy, selective cervical dissection (level VI). Morphological and immunohistochemical studies showed that cancer has a thymus-like differentiation (CASTLE). After 32 months, she recurred to the lymph nodes of the neck (level IV on the left). She underwent repeated surgery, after which she was observed without signs of relapse for 120 months. The rarity of the pathology leads to difficulties in establishing a diagnosis at the preoperative stage and in choosing the optimal treatment tactics during treatment and further follow-up.
- Open Access
- 2 May 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (2) , 29-36
CHEMORADIOTHERAPY FOR ORAL CANCER USING HYPERFRACTIONATED RADIATION SCHEDULE
ХИМИОЛУЧЕВАЯ ТЕРАПИЯ БОЛЬНЫХ РАКОМ СЛИЗИСТОЙ ОБОЛОЧКИ ПОЛОСТИ РТА С ИСПОЛЬЗОВАНИЕМ ГИПЕРФРАКЦИОНИРОВАНИЯ ДОЗЫ ОБЛУЧЕНИЯ
- 2 May 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (2) , 29-36
Open AccessCHEMORADIOTHERAPY FOR ORAL CANCER USING HYPERFRACTIONATED RADIATION SCHEDULE
ХИМИОЛУЧЕВАЯ ТЕРАПИЯ БОЛЬНЫХ РАКОМ СЛИЗИСТОЙ ОБОЛОЧКИ ПОЛОСТИ РТА С ИСПОЛЬЗОВАНИЕМ ГИПЕРФРАКЦИОНИРОВАНИЯ ДОЗЫ ОБЛУЧЕНИЯ
- Open Access
- 16 December 2020
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 10 (4) , 44-49
Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
Dermal toxicity of anti-cancer drugs apparent in patients with thyroid cancer. This side effect appears, in particular, in relation to increased administration of targeted anti-cancer treatment, especially tyrosinkinase inhibitors, towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumor cell. Our article focuses on the dermatotoxity, designated also as skin reaction, which most frequently occurs in patients treated by tyrosinkinase inhibitors – sorafenib, vandetonib, cabozantinib and lenvantinib. High prevalence of dermatotoxity, reported by patients, treated with these drugs underscores the need for greater understanding of the pathogenesis and management of this syndrome.
- 16 December 2020
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 10 (4) , 44-49
Open AccessSide skin reactions of multikinase inhibitors in treatment of thyroid cancer
Dermal toxicity of anti-cancer drugs apparent in patients with thyroid cancer. This side effect appears, in particular, in relation to increased administration of targeted anti-cancer treatment, especially tyrosinkinase inhibitors, towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumor cell. Our article focuses on the dermatotoxity, designated also as skin reaction, which most frequently occurs in patients treated by tyrosinkinase inhibitors – sorafenib, vandetonib, cabozantinib and lenvantinib. High prevalence of dermatotoxity, reported by patients, treated with these drugs underscores the need for greater understanding of the pathogenesis and management of this syndrome.
- Open Access
- 31 October 2019
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 9 (3) , 77-82
Solitary metastasis of the clear cell variant of renal cell carcinoma into the thyroid gland
Clinical case of solitary metastasis of the clear cell variant of renal cell carcinoma into the thyroid gland was analyzed. The thyroid mass was initially considered to be benign. The diagnostic showed signs similar to thyroid follicular neoplasia. The patient was operated on. The thyroid tumor was finally diagnosed as metastasis from clear cell variant of renal cell carcinoma.
- 31 October 2019
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 9 (3) , 77-82
Open AccessSolitary metastasis of the clear cell variant of renal cell carcinoma into the thyroid gland
Clinical case of solitary metastasis of the clear cell variant of renal cell carcinoma into the thyroid gland was analyzed. The thyroid mass was initially considered to be benign. The diagnostic showed signs similar to thyroid follicular neoplasia. The patient was operated on. The thyroid tumor was finally diagnosed as metastasis from clear cell variant of renal cell carcinoma.
- Open Access
- 31 October 2019
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 9 (3) , 72-76
Malignant peripheral nerve sheath tumor in the maxilla. Clinical сase
A clinical case of the malignant peripheral nerve sheath tumor is presented. It is a rare tumor in the head and neck area. The tumor arises from Schwann cells, its malignant potential is unclear. This low-growing tumor is presenting as a solitary nodule. To make a precise diagnosis immunohistochemistry assay is used. Surgical approach provides good long-term outcome.
- 31 October 2019
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 9 (3) , 72-76
Open AccessMalignant peripheral nerve sheath tumor in the maxilla. Clinical сase
A clinical case of the malignant peripheral nerve sheath tumor is presented. It is a rare tumor in the head and neck area. The tumor arises from Schwann cells, its malignant potential is unclear. This low-growing tumor is presenting as a solitary nodule. To make a precise diagnosis immunohistochemistry assay is used. Surgical approach provides good long-term outcome.
- Open Access
- 7 November 2018
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 8 (3) , 72-76
Efficacy of external beam radiotherapy and targeted therapy with vandenanib in patients with inoperable and progressive medullary thyroid cancer
The study objective is to evaluate modern-era radiotherapy (external beam radiotherapy, EBRT) and target therapy (TT) outcomes for advanced medullary thyroid cancer (MTC).Materials and methods. Seventy eight consecutive patients with stage IV MTC were evaluated. All of them with relapsing locally advanced or metastatic MTC, 16 had clinically relevant mediastinal involvement, and 59 had distant metastasis; 26 patients received conformal EBRT or intensity-modulated radiotherapy in monomode, 16 patients – conformal EBRT with simultaneous TT with vandenanib, 36 patients – TT in monomode. Median EBRT dose was 60 Gy.Results. Kaplan–Meier estimates of the median overall survival rate was 14 months for radiotherapy in monomode, 48 months – for conformal EBRT + simultaneous TT with vandenanib, 50 months – for TT in monomode. EBRT and TT allows for significantly shorter periods (median 3.8 weeks), to relieve the symptoms of compression-mediated organs and structures of the neck and mediastinum than in the TT (median 10.2 weeks) (p 0.001).Conclusion. EBRT and TT provided durable locoregional disease control with limited morbidity.
- 7 November 2018
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 8 (3) , 72-76
Open AccessEfficacy of external beam radiotherapy and targeted therapy with vandenanib in patients with inoperable and progressive medullary thyroid cancer
The study objective is to evaluate modern-era radiotherapy (external beam radiotherapy, EBRT) and target therapy (TT) outcomes for advanced medullary thyroid cancer (MTC).Materials and methods. Seventy eight consecutive patients with stage IV MTC were evaluated. All of them with relapsing locally advanced or metastatic MTC, 16 had clinically relevant mediastinal involvement, and 59 had distant metastasis; 26 patients received conformal EBRT or intensity-modulated radiotherapy in monomode, 16 patients – conformal EBRT with simultaneous TT with vandenanib, 36 patients – TT in monomode. Median EBRT dose was 60 Gy.Results. Kaplan–Meier estimates of the median overall survival rate was 14 months for radiotherapy in monomode, 48 months – for conformal EBRT + simultaneous TT with vandenanib, 50 months – for TT in monomode. EBRT and TT allows for significantly shorter periods (median 3.8 weeks), to relieve the symptoms of compression-mediated organs and structures of the neck and mediastinum than in the TT (median 10.2 weeks) (p 0.001).Conclusion. EBRT and TT provided durable locoregional disease control with limited morbidity.
- 1 January 2016
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 5 (4) , 47
One-stage thyroidectomy with complete sternal removal and anterior chest wall resection for metastatic thyroid cancer
- 1 January 2016
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 5 (4) , 47
One-stage thyroidectomy with complete sternal removal and anterior chest wall resection for metastatic thyroid cancer